This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week, we will discuss yet another endothelin antagonist trial, on a background of flozins, in proteinuric CKD. Will flozins help breakthrough the endothelin badness?
This week, we will discuss the MYTEMP trial from Lancet. A cool idea, a cool cluster design. Warmly embraced by the Ontario dialysis community. But did it work?
This week, we will discuss the first new BP lowering drug in decades. Aprocitentan, a dual endothelin antagonist in a meticulously designed trial in resistant hypertension.
The AURORA-1 trial. Sparkling with hope for lupus nephritis. Will this make it easier for rheumatologists to prescribe a CNI? Can you overcome the sticker shock to examine the benefits and weaknesses of AURORA-1. Let’s dive in.
This week, we will discuss the (probably) final story in the timing of RRT in AKI story. We discussed ELAIN, AKIKI and STARRT AKI. Early dialysis is not a good idea. But how late can you go? Let’s see with AKIKI-2
The new generation of potassium binders bind potassium but can they improve patient outcomes? These second order questions are starting to be answered. Join us this week to discuss the use of patiromer and spironolactone in patients with resistant hypertension.The AMBER Study
Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?
This week we discuss the BICAR-ICU trial from France. In patients who are critically ill with metabolic acidosis, does giving bicarb help improve survival? More importantly, does it help with kidney outcomes? Join us to discuss
This is the summary of one of the three RDN trials we are discussing - SPYRAL HTN-OFF, which examined the effect of renal denervation in patients with mild hypertension, who were off medications.
Rapid steroid withdrawal after transplant. Can it be done safely and can it reduce the risk of diabetes after transplant? Find out in the next exciting edition of NephJC.